Skip to main content
Clinical Trials/NL-OMON38644
NL-OMON38644
Withdrawn
Not Applicable

Prevention guidelines for contrast-induced nephropathy in contrast-enhanced CT: Appropriate and cost-effective? The Amsterdam, Maastricht, Alkmaar, Contrast Induced Nephropathy-Guideline study (the AMACING study) - The AMACING study

Academisch Medisch Centrum0 sites2,000 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
acute kidney injury
Sponsor
Academisch Medisch Centrum
Enrollment
2000
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • All patients aged 18 years and above, scheduled to undergo elective contrast enhanced computed tomography (no emergency department or intensive care unit) with intravenous iodinated contrast material administration.
  • Patients with an indication for prophylactic intravenous hydration according to one of the Dutch CIN prevention guidelines will be eligible for randomization.
  • Indication is defined as: eGFR 30\-44 ml/min/1\.73m2; eGFR 45\-59 ml/min/1\.73m2 \& diabetes mellitus or \* 2 risk factors; Kahler\*s disease (multiple myeloma) / Waldenström\*s macroglobulinemia with small chain proteinuria. Risk factors include: age \>75, anaemia, use of nephrotoxic medication, cardiac or peripheral vascular disease.

Exclusion Criteria

  • Patients will only be included once in the RCT; no repeat inclusion for additional contrast enhanced CT examinations will occur.

Outcomes

Primary Outcomes

Not specified

Similar Trials